Junliang Lu1, Jie Gao1, Jing Zhang1, Jian Sun1, Huanwen Wu1, Xiaohua Shi1, Lianghong Teng2, Zhiyong Liang1. 1. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College People's Republic of China. 2. Department of Pathology, Xuanwu Hospital, Capital Medical University People's Republic of China.
Abstract
BACKGROUND: BRAF V600E is the most frequent genetic alteration in papillary thyroid carcinoma (PTC); there are ongoing conflicts on its association with regional lymph node metastasis. And we aimed to test this association in a referred sample in a single institute in China. METHODS: We analyzed BRAF V600E mutational status in the primary lesion of 150 PTC cases in Peking Union Medical College Hospital (PUMCH) and their corresponding lymph node metastasis (if present and available) using a validated Amplification Refractory Mutation System Polymerase Chain Reaction (ARMS-PCR) method. RESULTS: Among 150 PTC cases, 121 (80.6%) primary tumors harbored BRAF V600E mutation, 66.9% (81/121) and 79.3% (23/29) had regional lymph node metastasis (LNM) in cases detected with and without BRAF V600E mutation, respectively (P = 0.195). The BRAF V600E mutational status of most of the metastatic lesions was not different to that of their primary foci (73 out of 76 cases, 96.1%, Kappa value = 0.893). The 3 inconsistent cases were all mutation positive for primary tumors and mutation negative for LNM. CONCLUSION: No association was established between BRAF V600E mutation and regional lymph node metastasis in PTC in Chinese patients.
BACKGROUND:BRAFV600E is the most frequent genetic alteration in papillary thyroid carcinoma (PTC); there are ongoing conflicts on its association with regional lymph node metastasis. And we aimed to test this association in a referred sample in a single institute in China. METHODS: We analyzed BRAFV600E mutational status in the primary lesion of 150 PTC cases in Peking Union Medical College Hospital (PUMCH) and their corresponding lymph node metastasis (if present and available) using a validated Amplification Refractory Mutation System Polymerase Chain Reaction (ARMS-PCR) method. RESULTS: Among 150 PTC cases, 121 (80.6%) primary tumors harbored BRAFV600E mutation, 66.9% (81/121) and 79.3% (23/29) had regional lymph node metastasis (LNM) in cases detected with and without BRAFV600E mutation, respectively (P = 0.195). The BRAFV600E mutational status of most of the metastatic lesions was not different to that of their primary foci (73 out of 76 cases, 96.1%, Kappa value = 0.893). The 3 inconsistent cases were all mutation positive for primary tumors and mutation negative for LNM. CONCLUSION: No association was established between BRAFV600E mutation and regional lymph node metastasis in PTC in Chinese patients.
Authors: Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: Ralph P Tufano; Gilberto V Teixeira; Justin Bishop; Kathryn A Carson; Mingzhao Xing Journal: Medicine (Baltimore) Date: 2012-09 Impact factor: 1.889
Authors: G Riesco-Eizaguirre; P Gutiérrez-Martínez; M A García-Cabezas; M Nistal; P Santisteban Journal: Endocr Relat Cancer Date: 2006-03 Impact factor: 5.678
Authors: Piro Lito; Christine A Pratilas; Eric W Joseph; Madhavi Tadi; Ensar Halilovic; Matthew Zubrowski; Alan Huang; Wai Lin Wong; Margaret K Callahan; Taha Merghoub; Jedd D Wolchok; Elisa de Stanchina; Sarat Chandarlapaty; Poulikos I Poulikakos; James A Fagin; Neal Rosen Journal: Cancer Cell Date: 2012-11-13 Impact factor: 31.743
Authors: C Durante; E Puxeddu; E Ferretti; R Morisi; S Moretti; R Bruno; F Barbi; N Avenia; A Scipioni; A Verrienti; E Tosi; A Cavaliere; A Gulino; S Filetti; D Russo Journal: J Clin Endocrinol Metab Date: 2007-05-08 Impact factor: 5.958
Authors: Gina M Howell; Marina N Nikiforova; Sally E Carty; Michaele J Armstrong; Steven P Hodak; Michael T Stang; Kelly L McCoy; Yuri E Nikiforov; Linwah Yip Journal: Ann Surg Oncol Date: 2012-09-01 Impact factor: 5.344
Authors: Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245